These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30373890)

  • 1. Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers.
    Buzkova J; Nikkanen J; Ahola S; Hakonen AH; Sevastianova K; Hovinen T; Yki-Järvinen H; Pietiläinen KH; Lönnqvist T; Velagapudi V; Carroll CJ; Suomalainen A
    EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30373890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling inclusion body myositis using a patient-derived fibroblast model.
    Cantó-Santos J; Valls-Roca L; Tobías E; García-García FJ; Guitart-Mampel M; Esteve-Codina A; Martín-Mur B; Casado M; Artuch R; Solsona-Vilarrasa E; Fernandez-Checa JC; García-Ruiz C; Rentero C; Enrich C; Moreno-Lozano PJ; Milisenda JC; Cardellach F; Grau-Junyent JM; Garrabou G
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):964-977. PubMed ID: 36860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inclusion body myositis (IBM) -- a review].
    Czaplinski A; Renaud S; Fuhr P
    Praxis (Bern 1994); 2003 Apr; 92(14):649-54. PubMed ID: 12723314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.
    Hiniker A; Daniels BH; Lee HS; Margeta M
    Acta Neuropathol Commun; 2013 Jul; 1():29. PubMed ID: 24252466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion body myositis with early onset: a population-based study.
    Lindgren U; Hedberg-Oldfors C; Pullerits R; Lindberg C; Oldfors A
    J Neurol; 2023 Nov; 270(11):5483-5492. PubMed ID: 37498322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion body myositis in patients with spinocerebellar ataxia types 3 and 6.
    Rietveld A; van Gaalen J; Saris C; Okkersen K; Küsters B; van de Warrenburg B; van Engelen B; Sacconi S; Raaphorst J
    J Neurol Neurosurg Psychiatry; 2020 Aug; 91(8):876-878. PubMed ID: 32576615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion body myositis.
    Dimachkie MM; Barohn RJ
    Neurol Clin; 2014 Aug; 32(3):629-46, vii. PubMed ID: 25037082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras.
    De Paepe B
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30621041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion Body Myositis.
    Goyal NA
    Continuum (Minneap Minn); 2022 Dec; 28(6):1663-1677. PubMed ID: 36537974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.
    Esterhuizen K; Lindeque JZ; Mason S; van der Westhuizen FH; Rodenburg RJ; de Laat P; Smeitink JAM; Janssen MCH; Louw R
    Metabolomics; 2021 Jan; 17(1):10. PubMed ID: 33438095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials.
    Cortese A; Machado P; Morrow J; Dewar L; Hiscock A; Miller A; Brady S; Hilton-Jones D; Parton M; Hanna MG
    Neuromuscul Disord; 2013 May; 23(5):404-12. PubMed ID: 23489664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing developments in sporadic inclusion body myositis.
    Machado PM; Ahmed M; Brady S; Gang Q; Healy E; Morrow JM; Wallace AC; Dewar L; Ramdharry G; Parton M; Holton JL; Houlden H; Greensmith L; Hanna MG
    Curr Rheumatol Rep; 2014 Dec; 16(12):477. PubMed ID: 25399751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.
    Brady S; Squier W; Sewry C; Hanna M; Hilton-Jones D; Holton JL
    BMJ Open; 2014 Apr; 4(4):e004552. PubMed ID: 24776709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.
    Michelle EH; Pinal-Fernandez I; Casal-Dominguez M; Albayda J; Paik JJ; Tiniakou E; Adler B; Mecoli CA; Danoff SK; Christopher-Stine L; Mammen AL; Lloyd TE
    Neurology; 2023 Mar; 100(13):e1406-e1417. PubMed ID: 36690456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.
    Chahin N; Engel AG
    Neurology; 2008 Feb; 70(6):418-24. PubMed ID: 17881720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis.
    Tasca G; Monforte M; De Fino C; Kley RA; Ricci E; Mirabella M
    Muscle Nerve; 2015 Dec; 52(6):956-62. PubMed ID: 25808807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional relevance of mitochondrial abnormalities in sporadic inclusion body myositis.
    Joshi PR; Vetterke M; Hauburger A; Tacik P; Stoltenburg G; Hanisch F
    J Clin Neurosci; 2014 Nov; 21(11):1959-63. PubMed ID: 25311418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of inclusion body myositis.
    Greenberg SA
    Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion body myositis (IBM).
    Gayathri N; Anisya-Vasanth ; Veerendra Kumar M; Das S; Santosh V; Yasha TC; Ramamohan Y; Taly AB; Gourie-Devi M; Shankar SK
    Clin Neuropathol; 2000; 19(1):13-20. PubMed ID: 10774946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing.
    Hedberg-Oldfors C; Lindgren U; Basu S; Visuttijai K; Lindberg C; Falkenberg M; Larsson Lekholm E; Oldfors A
    Brain Pathol; 2021 May; 31(3):e12931. PubMed ID: 33354847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.